Clinical Trial Update: Sintilimab Plus NCT or NCRT Versus NCRT for ESCC [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Sintilimab plus NCT or NCRT versus NCRT for Esophageal Squamous Cell Carcinoma is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Sintilimab (sintilimab)

Snippet

Sponsor: Sichuan Cancer Hospital and Research Institute | Conditions: Esophageal Squamous Cell Carcinoma | Phase 3 | Status: NOT_YET_RECRUITING